Article
Clinical Neurology
Hee-Jin Kim, YongSoo Shim, Hyun Jeong Han, Byeong C. C. Kim, Kee Hyung Park, So Young Moon, Seong Hye Choi, Dong Won Yang, Bora Yoon, Eun-Joo Kim, Jee Hyang Jeong, Seol-Heui Han
Summary: This study aimed to evaluate the effectiveness of memantine on speech function in patients with moderate to severe Alzheimer's disease who were already on donepezil therapy. The results showed that although the combination therapy was not superior to monotherapy, memantine was still effective in improving behavioral symptoms.
NEUROLOGY AND THERAPY
(2023)
Article
Chemistry, Medicinal
Dariusz Swietlik, Jacek Bialowas, Aida Kusiak, Marta Krasny
Summary: This in silico study suggests that memantine monotherapy is effective in treating moderate to severe Alzheimer's disease, as evaluated by various neuronal parameters. The results provide a different perspective on clinical trials and further understanding of the variability in trial outcomes.
Article
Medicine, Research & Experimental
Mayank Handa, Sachin Nashik Sanap, Rabi Sankar Bhatta, Gajanan Pratap Patil, Rajendra Palkhade, Dhirendra Pratap Singh, Rahul Shukla
Summary: This study aims to develop nanoemulsions for the simultaneous delivery of donepezil and memantine for enhanced brain delivery via the intranasal route. The nanoemulsion was prepared using a low energy emulsification method and characterized using various microscopy techniques. The results demonstrate that the intranasal administration of the nanoemulsion leads to higher brain concentration and better pharmacodynamic effects compared to other routes of administration.
MOLECULAR PHARMACEUTICS
(2023)
Review
Pharmacology & Pharmacy
Debora Nunes, Joana A. Loureiro, Maria Carmo Pereira
Summary: Alzheimer's disease is the most common form of dementia, requiring the development of more effective treatment strategies. Approved drugs for treatment have limited effectiveness and unwanted side effects. Utilizing drug delivery systems can enhance drug efficacy and reduce unwanted side effects.
Article
Neurosciences
Yu Nakamura, Takumi Omori, Rei Kim, Kenichi Nishiyama, Takashi Kikuchi, Ichiro Ishikawa, Hiroshi Aoki
Summary: This study evaluated the safety and efficacy of a 27.5 mg donepezil patch for 52 weeks in patients with mild-to-moderate Alzheimer's disease, as well as the safety of switching from tablets to the patch. The results showed that the patch application for 52 weeks was well tolerated and feasible, including switching from tablets.
JOURNAL OF ALZHEIMERS DISEASE
(2023)
Article
Materials Science, Biomaterials
Mayank Handa, Sachin Nashik Sanap, Rabi Sankar Bhatta, Gajanan Pratap Patil, Suchetana Ghose, Dhirendra Pratap Singh, Rahul Shukla
Summary: This study focuses on the development of mannose-coated PLGA nanoparticles for delivering Donepezil and Memantine. The results show that intranasal administration of the coated nanoparticles leads to higher drug concentration and superior efficacy in neurobehavioral assessments, gene expression analyses, and biochemical estimations.
BIOMATERIALS ADVANCES
(2023)
Article
Geriatrics & Gerontology
Yu Nakamura, Rei Kim, Kenichi Nishiyama, Takashi Kikuchi, Ichiro Ishikawa, Hiroshi Aoki
Summary: This study aimed to evaluate the non-inferiority of a 27.5 mg donepezil patch compared with 5 mg donepezil hydrochloride tablets in patients with mild-to-moderate Alzheimer's disease, and to compare their efficacy and safety profiles. The results showed that the 27.5 mg donepezil patch was non-inferior to the 5 mg donepezil hydrochloride tablets in suppressing cognitive decline, and had a comparable safety profile.
GERIATRICS & GERONTOLOGY INTERNATIONAL
(2023)
Article
Medicine, General & Internal
Jonathan I. Silverberg, Emma Guttman-Yassky, Diamant Thaci, Alan D. Irvine, Linda Stein Gold, Andrew Blauvelt, Eric L. Simpson, Chia-Yu Chu, Zhuqing Liu, Renata Gontijo Lima, Sreekumar G. Pillai, Julien Seneschal
Summary: The study shows that lebrikizumab is effective in treating moderate-to-severe atopic dermatitis in both adolescents and adults, with significant improvements in skin lesions and reduction of itch symptoms during the 16-week induction period.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Medicine, General & Internal
Jonathan I. Silverberg, Emma Guttman-Yassky, Diamant Thaci, Alan D. Irvine, Linda Stein Gold, Andrew Blauvelt, Eric L. Simpson, Chia-Yu Chu, Zhuqing Liu, Renata Gontijo Lima, Sreekumar G. Pillai, Julien Seneschal
Summary: Two 52-week trials showed that treatment with lebrikizumab was effective in improving skin condition and reducing itch severity in patients with moderate-to-severe atopic dermatitis. The incidence of adverse events was generally mild to moderate and did not lead to trial discontinuation.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Review
Geriatrics & Gerontology
Adrian L. Knorz, Arnim Quante
Summary: Combination drug therapy may have slight benefits for some patients with moderate to severe AD, but evidence remains unclear and further research is needed. Utilizing appropriate ChEI monotherapy alone may also not miss major cognitive benefits.
JOURNAL OF GERIATRIC PSYCHIATRY AND NEUROLOGY
(2022)
Review
Clinical Neurology
M. Seibert, V Muehlbauer, J. Holbrook, S. Voigt-Radloff, S. Brefka, D. Dallmeier, M. Denkinger, C. Schoenfeldt-Lecuona, S. Kloeppel, C. A. F. von Arnim
Summary: This systematic review evaluated the efficacy and safety of pharmacotherapy in AD patients with frailty or significant functional impairments. Despite limited evidence, the studies suggest that some drug therapies might have slight benefits for cognition in these patients, but the quality of evidence is low. More clinical trials focusing on frail older adults are urgently needed to provide specific recommendations for drug therapy in this population.
ALZHEIMERS RESEARCH & THERAPY
(2021)
Article
Clinical Neurology
Richard B. Lipton, David W. Dodick, Peter J. Goadsby, Rami Burstein, Aubrey M. Adams, Jeff Lai, Sung Yun Yu, Michelle Finnegan, Amy W. Kuang, Joel M. Trugman
Summary: This study aimed to compare the efficacy of ubrogepant in treating migraine with mild vs moderate or severe pain. The results showed that ubrogepant treatment during mild pain significantly increased the rates of pain freedom, freedom from associated symptoms, and achieving normal function.
Article
Dermatology
Georgios Kokolakis, Richard B. Warren, Bruce Strober, Andrew Blauvelt, Luis Puig, Akimichi Morita, Melinda Gooderham, Andreas Koerber, Veerle Vanvoorden, Maggie Wang, Dirk de Cuyper, Cynthia Madden, Natalie Nunez Gomez, Mark Lebwohl
Summary: This study evaluated the efficacy and safety of switching to bimekizumab from adalimumab, ustekinumab, and secukinumab. The results showed rapid and durable improvements in clinical responses among nonresponders who switched to bimekizumab. Furthermore, the majority of patients who responded well to previous treatments maintained or improved their response after switching to bimekizumab. Overall, switching to bimekizumab was found to be highly effective and well tolerated for psoriasis patients.
BRITISH JOURNAL OF DERMATOLOGY
(2023)
Article
Neurosciences
Kazufumi Yoshida, Michael Seo, Yan Luo, Ethan Sahker, Andrea Cipriani, Stefan Leucht, Takeshi Iwatsubo, Orestis Efthimiou, Toshiaki A. Furukawa
Summary: This study developed a personalized prediction model for Alzheimer's disease patients and estimated patient-specific treatment effects of donepezil. Results indicated that donepezil has some efficacy for cognitive function in most patients with AD, but the efficacy may be reduced when combined with antipsychotic drug use.
JOURNAL OF ALZHEIMERS DISEASE
(2022)
Article
Medicine, General & Internal
Michael E. Wechsler, Marcella K. Ruddy, Ian D. Pavord, Elliot Israel, Klaus F. Rabe, Linda B. Ford, Jorge F. Maspero, Raolat M. Abdulai, Chih-Chi Hu, Renata Martincova, Andreas Jessel, Michael C. Nivens, Nikhil Amin, David M. Weinreich, George D. Yancopoulos, Helene Goulaouic
Summary: The study found that the monoclonal antibody itepekimab targeting interleukin-33 was more effective than placebo in improving lung function and reducing the incidence of loss of asthma control events in patients with moderate-to-severe asthma.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Physiology
Daniele Tomassoni, Enea Traini, Manuele Mancini, Vincenzo Bramanti, Syed Sarosh Mahdi, Francesco Amenta
AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY
(2015)
Article
Neurosciences
Anna Carotenuto, Raffaele Rea, Enea Traini, Angiola Maria Fasanaro, Giovanna Ricci, Valentino Manzo, Francesco Amenta
JOURNAL OF ALZHEIMERS DISEASE
(2017)
Article
Neurosciences
Francesco Amenta, Anna Carotenuto, Angiola Maria Fasanaro, Raffaele Rea, Enea Traini
JOURNAL OF ALZHEIMERS DISEASE
(2014)
Article
Neurosciences
S. Grasso, V. Bramanti, D. Tomassoni, D. Bronzi, G. Malfa, E. Traini, M. Napoli, M. Renis, F. Amenta, R. Avola
JOURNAL OF NEUROSCIENCE RESEARCH
(2014)
Article
Neurosciences
V. Bramanti, S. Grasso, D. Tomassoni, E. Traini, G. Raciti, M. Viola, G. Li Volti, A. Campisi, F. Amenta, R. Avola
JOURNAL OF NEUROSCIENCE RESEARCH
(2015)
Article
Geriatrics & Gerontology
Daniele Tomassoni, Enea Traini, Francesco Amenta
Article
Public, Environmental & Occupational Health
Giulio Nittari, Daniele Tomassoni, Marzio Di Canio, Enea Traini, Isabel Pirillo, Andrea Minciacchi, Francesco Amenta
Article
Behavioral Sciences
Raffaele Rea, Enea Traini, Rosaria Renna, Francesco Pagliuca, Marianna Pezzella, Mauro Pagliuca
EPILEPSY & BEHAVIOR
(2019)
Article
Pharmacology & Pharmacy
Simone Baldoni, Graziano Pallotta, Enea Traini, Getu G. Sagaro, Giulio Nittari, Francesco Amenta
PHARMACY PRACTICE-GRANADA
(2020)
Article
Integrative & Complementary Medicine
Pierluigi Pompei, Iolanda Grappasonni, Stefania Scuri, Fabio Petrelli, Enea Traini, Sacha Sorrentino, Giuseppe Di Fede
ALTERNATIVE THERAPIES IN HEALTH AND MEDICINE
(2019)
Article
Psychiatry
Anna Carotenuto, Raffaele Rea, Enea Traini, Giovanna Ricci, Angiola Maria Fasanaro, Francesco Amenta
JMIR MENTAL HEALTH
(2018)
Article
Public, Environmental & Occupational Health
Giulio Nittari, Graziano Pallotta, Marzio Di Canio, Enea Traini, Francesco Amenta
INTERNATIONAL MARITIME HEALTH
(2018)
Review
Neurosciences
Ilenia Martinelli, Daniele Tomassoni, Michele Moruzzi, Enea Traini, Francesco Amenta, Seyed Khosrow Tayebati
CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS
(2017)
Article
Public, Environmental & Occupational Health
Iolanda Grappasonni, Fabio Petrelli, Enea Traini, Giuliana Grifantini, Massimo Mari, Carlo Signorelli
EPIDEMIOLOGY BIOSTATISTICS AND PUBLIC HEALTH
(2017)
Article
Neurosciences
Raffaele Rea, Anna Carotenuto, Enea Traini, Angiola Maria Fasanaro, Valentino Manzo, Francesco Amenta
JOURNAL OF ALZHEIMERS DISEASE
(2015)